Pharmacokinetic and Pharmacodynamic of Rocuronium

Pontificia Universidad Catolica de Chile

Status: Completed

Conditions: Neuromuscular Blockade

Treatments: Drug: Rocuronium Bromide

Study type: Observational

Funder types: Other

Identifiers

NCT02376595

12-003

Details and patient eligibility

About

The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.

Enrollment: 10 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Scheduled for elective surgery under general anesthesia.

Exclusion criteria

• Pregnancy.
• Body mass index (BMI) >25 kg/m2.
• Anticipated difficult airway.
• Surgery associated with great volume loss.
• Presence of any neuromuscular, hepatic, renal, cardiac or respiratory disease.
• Previous history of neuromuscular blockade allergy, and/or administration of drugs known to interfere with neuromuscular blockade

Trial design

10 participants in 1 patient group

Rocuronium Bromide

Description:

Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.

Treatment:

Drug: Rocuronium Bromide